Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 11026 results:
[ Συντάκτης(Asc)] Τίτλος Τύπος Έτος
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Z
Zarogoulidis, P., Kioumis I., Tsiouda T., Pezirkianidis N., Ritzoulis C., Huang H., et al. (2014).  A 3D Polymer Model for Future Nutrition Design Novel Nutrition Approach for Cystic Fibrosis, Ulcerative Colitis and Crohn's Disease.. J Nanomedine Biotherapeutic Discov. 4(2), 128.
Zarogoulidis, P., Huang H., Tsiouda T., Sardeli C., Trakada G., Veletza L., et al. (2017).  Immunotherapy "Shock" with vitiligo due to nivolumab administration as third line therapy in lung adenocarcinoma.. Respir Med Case Rep. 22, 283-286.
Zarogoulidis, P., Sapalidis K., Kosmidis C., Tsakiridis K., Huang H., Bai C., et al. (2020).  Stents for small airways: current practice.. Expert Rev Respir Med. 14(10), 969-972.
Zarogoulidis, P., Alexandropoulou I., Romanidou G., Konstasntinidis T. G., Terzi E., Saridou S., et al. (2011).  Community-acquired pneumonia due to Legionella pneumophila, the utility of PCR, and a review of the antibiotics used.. Int J Gen Med. 4, 15-9.
Zarogoulidis, P., Chatzaki E., Hohenforst-Schmidt W., Goldberg E. P., Galaktidou G., Kontakiotis T., et al. (2012).  Management of malignant pleural effusion by suicide gene therapy in advanced stage lung cancer: a case series and literature review.. Cancer Gene Ther. 19(9), 593-600.
Zarogoulidis, P., Yarmus L., & Zarogoulidis K. (2013).  New insights for IL-6 targeted therapy as an adjuvant treatment for non-small-cell lung cancer.. Ther Deliv. 4(10), 1221-3.
Zarogoulidis, K., Boutsikou E., Zarogoulidis P., Darwiche K., Freitag L., Porpodis K., et al. (2013).  The role of second-line chemotherapy in small cell lung cancer: a retrospective analysis.. Onco Targets Ther. 6, 1493-500.
Zarogoulidis, P., Chinelis P., Athanasiadou A., Tsiouda T., Trakada G., Kallianos A., et al. (2017).  Possible adverse effects of immunotherapy in non-small cell lung cancer; treatment and follow-up of three cases.. Respir Med Case Rep. 22, 101-105.
Zarogoulidis, P., Kosmidis C., Fyntanidou V., Barmpas A., Koulouris C., Aidoni Z., et al. (2019).  Elastography during convex-probe (endobronchial ultrasound) for optimal biopsy sample and gene identification in non-small-cell lung cancer.. Biomark Med. 13(14), 1153-1156.
Zarogoulidis, P., Trakada G., & Zarogoulidis K. (2013).  A chrono-target chemotherapy treatment model for lung cancer treatment.. Ther Deliv. 4(1), 5-8.
Zarogoulidis, P., Hohenforst-Schmidt W., Huang H., Sapalidis K., Kosmidis C., Tryfon S., et al. (2020).  Vapor for lung volume reduction; pros and cons.. Expert Rev Respir Med. 14(12), 1189-1195.
Zarogoulidis, P., Petridis D., Ritzoulis C., Darwiche K., Spyratos D., Huang H., et al. (2013).  Establishing the optimal nebulization system for paclitaxel, docetaxel, cisplatin, carboplatin and gemcitabine: back to drawing the residual cup.. Int J Pharm. 453(2), 480-7.
Zarogoulidis, P., Terzi E., Kouliatsis G., Androuli S., Kontakiotis T., Zaramboucas T., et al. (2011).  Orbital metastases as the first manifestation of lung adenocarcinoma.. Case Rep Ophthalmol. 2(1), 34-8.
Zarogoulidis, P., Papadopoulos V., Maragouli E., Papatsibas G., Sardeli C., Man Y-G., et al. (2018).  Nivolumab as first-line treatment in non-small cell lung cancer patients-key factors: tumor mutation burden and PD-L1 ≥50.. Transl Lung Cancer Res. 7(Suppl 1), S28-S30.
Zarogoulidis, P., Petridis D., Ritzoulis C., Li Q., Huang H., Ning Y., et al. (2013).  Further experimentation of inhaled; LANTUS, ACTRAPID and HUMULIN with todays' production systems.. Int J Pharm. 458(1), 39-47.
Zarogoulidis, P., Kouliatsis G., Papanas N., Spyratos D., Constantinidis T. C., Kouroumichakis I., et al. (2011).  Long-term respiratory follow-up of H1N1 infection.. Virol J. 8, 319.
Zarogoulidis, P., Kioumis I., Ritzoulis C., Petridis D., Darwiche K., Porpodis K., et al. (2013).  New insights in the production of aerosol antibiotics. Evaluation of the optimal aerosol production system for ampicillin-sulbactam, meropenem, ceftazidime, cefepime and piperacillin-tazobactam.. Int J Pharm. 455(1-2), 182-8.
Zarogoulidis, P., Darwiche K., Krauss L., Huang H., Zachariadis G. A., Katsavou A., et al. (2013).  Inhaled cisplatin deposition and distribution in lymph nodes in stage II lung cancer patients.. Future Oncol. 9(9), 1307-13.
Zarogoulidis, P., Katsikogianni F., Tsiouda T., Sakkas A., Katsikogiannis N., & Zarogoulidis K. (2014).  Interleukin-8 and interleukin-17 for cancer.. Cancer Invest. 32(5), 197-205.
Zarogoulidis, P., Porpodis K., Kioumis I., Petridis D., Lampaki S., Spyratos D., et al. (2014).  Experimentation with inhaled bronchodilators and corticosteroids.. Int J Pharm. 461(1-2), 411-8.
Zarogoulidis, K., Zarogoulidis P., Darwiche K., Tsakiridis K., Machairiotis N., Kougioumtzi I., et al. (2013).  Malignant pleural effusion and algorithm management.. J Thorac Dis. 5 Suppl 4, S413-9.
Zarogoulidis, P., Christakidis V., Petridis D., Sapalidis K., Kosmidis C., Vagionas A., et al. (2020).  Connection between PD-L1 expression and standardized uptake value in NSCLC: an early prognostic treatment combination.. Expert Rev Respir Med.
Zarogoulidis, P., Kioumis I., Papanas N., Manika K., Kontakiotis T., Papagianis A., et al. (2012).  The effect of combination IFN-alpha-2a with usual antituberculosis chemotherapy in non-responding tuberculosis and diabetes mellitus: a case report and review of the literature.. J Chemother. 24(3), 173-7.
Zarogoulidis, P., Kioumis I., Porpodis K., Spyratos D., Tsakiridis K., Huang H., et al. (2013).  Clinical experimentation with aerosol antibiotics: current and future methods of administration.. Drug Des Devel Ther. 7, 1115-34.
Zarogoulidis, P., Orfanidis M., Constadinidis T. C., Eleutheriadou E., Kontakiotis T., Kerenidi T., et al. (2011).  A 26-year-old male with mesothelioma due to asbestos exposure.. Case Rep Med. 2011, 951732.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.